Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty.

Liang Y, Wei H, Zhang J, Hou L, Luo X

Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban1 Jan 2006Cited by 4 (Europe PMC)

PMID17219967DOI10.1007/s11596-006-0519-2PepBankPUB-17219967

Publisher page PubMedAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, both triptorelin regimens caused regression of precocious puberty and reversal of secondary sexual characteristics.
In plain wordsIn girls with precocious puberty, both triptorelin regimens reversed pubertal signs compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePrecocious puberty regression
Study
n = 46
Comparator
Before treatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
It was found that both treatment regimes led to regression of precocious puberty and reversal of secondary sexual characteristics.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996701
02HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, breast development regressed during triptorelin therapy.
In plain wordsIn girls with precocious puberty, breast development regressed during triptorelin treatment compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBreast development
Study
n = 46
Comparator
Before treatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
Breast developments regressed.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996702
03HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, uterine volume decreased nonsignificantly after triptorelin treatment.
In plain wordsIn girls with precocious puberty, uterine volume did not change significantly after triptorelin compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeUterine volume
Study
n = 46
Comparator
Before treatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
Uterine volume was decreased after treatment, but there was no statistically significant difference.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996703
04HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, mean ovarian volume did not change significantly during triptorelin treatment.
In plain wordsIn girls with precocious puberty, ovarian volume did not change significantly during triptorelin compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOvarian volume
Study
n = 46
Comparator
Before treatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
Mean ovarian volume did not change significantly during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996704
05HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, predicted adult height increased significantly and progressively during triptorelin therapy.
In plain wordsIn girls with precocious puberty, triptorelin increased predicted adult height compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePredicted adult height
Study
n = 46
Comparator
Before treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The predicted adult height was increased significantly and progressively during therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996709
06HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, serum LH returned to prepubertal levels during triptorelin therapy.
In plain wordsIn girls with precocious puberty, triptorelin reduced serum LH to prepubertal levels compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum LH
Study
n = 46
Comparator
Before treatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The levels of serum LH, FSH and E2 returned to the prepubertal condition.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996710
07HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, serum FSH returned to prepubertal levels during triptorelin therapy.
In plain wordsIn girls with precocious puberty, triptorelin reduced serum FSH to prepubertal levels compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum FSH
Study
n = 46
Comparator
Before treatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The levels of serum LH, FSH and E2 returned to the prepubertal condition.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996711
08HumanRandomized controlled trialEfficacy outcome
In girls with idiopathic central precocious puberty, serum E2 returned to prepubertal levels during triptorelin therapy.
In plain wordsIn girls with precocious puberty, triptorelin reduced serum E2 to prepubertal levels compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum estradiol
Study
n = 46
Comparator
Before treatment
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
The levels of serum LH, FSH and E2 returned to the prepubertal condition.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996712
09HumanRandomized controlled trialSafety outcome
In girls with idiopathic central precocious puberty, no significant side effects were reported during triptorelin therapy.
In plain wordsIn girls with precocious puberty, no significant side effects were reported during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSignificant side effects
Study
n = 46
Outcome group
Adverse events · Whole body
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Source sentences
Summary
No significant side effects of therapy were noted.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996713
10HumanRandomized controlled trialSafety outcome
In girls treated with triptorelin for precocious puberty, two had minimal withdrawal vaginal bleeding after the first injection.
In plain wordsIn girls treated with triptorelin for precocious puberty, two had minimal vaginal bleeding after the first injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableWithdrawal vaginal bleeding
Study
n = 46
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
3.75 mg · More than 12 monthsAs given in this study (human).
Measurements
Girls with withdrawal bleeding
2 girls
after first injection
Source sentences
Summary
Two girls had minimal withdrawal vaginal bleeding episodes after the first injection.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996715
11HumanRandomized controlled trialEfficacy outcome
In girls with precocious puberty, subcutaneous triptorelin significantly reduced height velocity from 6.3 to 5.8 cm/year.
In plain wordsIn girls with precocious puberty, subcutaneous triptorelin reduced height velocity from 6.3 to 5.8 cm/year compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseHeight velocity with subcutaneous regimen
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every 6 weeks · subcutaneous · More than 12 monthsAs given in this study (human).
Measurements
Height velocity
6.3 cm/year
SC before treatment
Height velocity
5.8 cm/year
SC after treatment
Source sentences
Summary
The height velocity was decreased significantly from 6.3+/-1.4 cm/year to 5.8+/-1.2 cm/year in group SC and 6.7+/-1.3 cm/year to 5.4+/-1.0 cm/year in group IM, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996705
12HumanRandomized controlled trialEfficacy outcome
In girls with precocious puberty, intramuscular triptorelin significantly reduced height velocity from 6.7 to 5.4 cm/year.
In plain wordsIn girls with precocious puberty, intramuscular triptorelin reduced height velocity from 6.7 to 5.4 cm/year compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseHeight velocity with intramuscular regimen
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every 4 weeks · intramuscular · More than 12 monthsAs given in this study (human).
Measurements
Height velocity
6.7 cm/year
IM before treatment
Height velocity
5.4 cm/year
IM after treatment
Source sentences
Summary
The height velocity was decreased significantly from 6.3+/-1.4 cm/year to 5.8+/-1.2 cm/year in group SC and 6.7+/-1.3 cm/year to 5.4+/-1.0 cm/year in group IM, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996706
13HumanRandomized controlled trialEfficacy outcome
In girls with precocious puberty, subcutaneous triptorelin reduced the bone-age to chronological-age change ratio from 1.2 to 0.7.
In plain wordsIn girls with precocious puberty, subcutaneous triptorelin reduced the bone maturation ratio from 1.2 to 0.7 compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone maturation rate with subcutaneous regimen
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
3.75 mg every 6 weeks · subcutaneous · More than 12 monthsAs given in this study (human).
Measurements
deltaBA/deltaCA
1.2 ratio
SC before treatment
deltaBA/deltaCA
0.7 ratio
SC after treatment
Source sentences
Summary
The ratio of deltaBA/deltaCA was 1.2+/-0.2 or 1.3+/-0.3 at the onset of therapy and decreased significantly after the treatment to 0.7+/-0.2 or 0.9+/-0.1, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The rate of bone maturation was reduced significantly during treatment.
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996707
14HumanRandomized controlled trialEfficacy outcome
In girls with precocious puberty, intramuscular triptorelin reduced the bone-age to chronological-age change ratio from 1.3 to 0.9.
In plain wordsIn girls with precocious puberty, intramuscular triptorelin reduced the bone maturation ratio from 1.3 to 0.9 compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone maturation rate with intramuscular regimen
Study
n: not reported in source
Comparator
Before treatment
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
3.75 mg every 4 weeks · intramuscular · More than 12 monthsAs given in this study (human).
Measurements
deltaBA/deltaCA
1.3 ratio
IM before treatment
deltaBA/deltaCA
0.9 ratio
IM after treatment
Source sentences
Summary
The ratio of deltaBA/deltaCA was 1.2+/-0.2 or 1.3+/-0.3 at the onset of therapy and decreased significantly after the treatment to 0.7+/-0.2 or 0.9+/-0.1, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The rate of bone maturation was reduced significantly during treatment.
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996708
15HumanRandomized controlled trialSafety outcome
In girls receiving subcutaneous triptorelin, a non-irritating injection-site mass was the most common side effect and resolved after 6-12 weeks.
In plain wordsIn girls receiving subcutaneous triptorelin, the most common side effect was an injection-site mass that resolved after 6-12 weeks.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableInjection-site mass
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Studied dose
3.75 mg every 6 weeks · subcutaneous · More than 12 monthsAs given in this study (human).
Measurements
Mass diameter
1 cm
subcutaneous injection site
Mass resolution
6 to 12 weeks
after injection
Source sentences
Summary
The most common side effect during SC treatment was that a non-irritating, 1 cm in diameter mass was palpated at the site of subcutaneous injection in the abdominal wall of patients, which disappeared after 6-12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa.
Summary · context
Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively.
Report a problemFND-1721996714

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.